SCHEMBL2397419

SCHEMBL2397419

CNC(=O)Cc1ccccc1-c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.51
LMNA P02545 2/20 0.51
RAB9A P51151 1/20 0.51
FFAR1 O14842 1/20 0.46
FFAR4 Q5NUL3 1/20 0.46
DPP4 P27487 1/20 0.46
FOLH1 Q04609 1/20 0.45
HDAC3 O15379 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
HDAC4 P56524 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
PDCD1 Q15116 1/20 0.44
CD274 Q9NZQ7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890714 0.87 CYP2C19 (0.49) KMT2AFFAR1FFAR4CHRM1CHRM3
SCHEMBL2393550 0.87 SLC6A3 (0.48) KMT2ALMNARAB9AFFAR1FFAR4
SCHEMBL2391383 0.87 SLC6A4 (0.49) KMT2ALMNARAB9AFFAR1FFAR4
SCHEMBL2394292 0.84 FFAR1 (0.47) KMT2ALMNAFFAR1FFAR4ALDH1A1
SCHEMBL2393439 0.83 SMN1; SMN2 (0.46) KMT2ALMNARAB9AFFAR1FFAR4
SCHEMBL9890716 0.83 CHRM1 (0.62) L3MBTL1CHRM1CHRM3
SCHEMBL9890735 0.83 CHRM1 (0.44) KMT2ALMNARAB9AHDAC1HDAC2
SCHEMBL2395131 0.83 KCNJ5 (0.49) LMNARAB9AFFAR1FFAR4HDAC4
SCHEMBL9890725 0.82 HDAC7 (0.50) KMT2ALMNARAB9AHDAC7PSMB5
SCHEMBL9890763 0.82 HDAC7 (0.47) KMT2ALMNARAB9AHDAC7ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US claimed
CN-102282124-A Biphenylacetamide derivative 2011-12-14 CN claimed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP claimed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US claimed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
CN-102282124-A Biphenylacetamide derivative 2011-12-14 CN disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 KMT2A 78/4885LMNA 3980/4885RAB9A 208/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 KMT2A 78/4885LMNA 3980/4885RAB9A 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.